Literature DB >> 23863621

Developmental differences in IFN signaling affect GATA1s-induced megakaryocyte hyperproliferation.

Andrew J Woo, Karen Wieland, Hui Huang, Thomas E Akie, Taylor Piers, Jonghwan Kim, Alan B Cantor.   

Abstract

About 10% of Down syndrome (DS) infants are born with a transient myeloproliferative disorder (DS-TMD) that spontaneously resolves within the first few months of life. About 20%-30% of these infants subsequently develop acute megakaryoblastic leukemia (DS-AMKL). Somatic mutations leading to the exclusive production of a short GATA1 isoform (GATA1s) occur in all cases of DS-TMD and DS-AMKL. Mice engineered to exclusively produce GATA1s have marked megakaryocytic progenitor (MkP) hyperproliferation during early fetal liver (FL) hematopoiesis, but not during postnatal BM hematopoiesis, mirroring the spontaneous resolution of DS-TMD. The mechanisms that underlie these developmental stage-specific effects are incompletely understood. Here, we report a striking upregulation of type I IFN-responsive gene expression in prospectively isolated mouse BM- versus FL-derived MkPs. Exogenous IFN-α markedly reduced the hyperproliferation FL-derived MkPs of GATA1s mice in vitro. Conversely, deletion of the α/β IFN receptor 1 (Ifnar1) gene or injection of neutralizing IFN-α/β antibodies increased the proliferation of BM-derived MkPs of GATA1s mice beyond the initial postnatal period. We also found that these differences existed in human FL versus BM megakaryocytes and that primary DS-TMD cells expressed type I IFN-responsive genes. We propose that increased type I IFN signaling contributes to the developmental stage-specific effects of GATA1s and possibly the spontaneous resolution of DS-TMD.

Entities:  

Year:  2013        PMID: 23863621      PMCID: PMC3726146          DOI: 10.1172/JCI40609

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  45 in total

Review 1.  Down syndrome and leukemia.

Authors:  L L Robison
Journal:  Leukemia       Date:  1992       Impact factor: 11.528

2.  Recombinant interferon-alpha, but not interferon-gamma is effective therapy for essential thrombocythemia.

Authors:  M J Abegg-Werter; J M Raemaekers; B E de Pauw; C Haanen
Journal:  Blut       Date:  1990-01

3.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

4.  GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome.

Authors:  Johann K Hitzler; Joseph Cheung; Yue Li; Stephen W Scherer; Alvin Zipursky
Journal:  Blood       Date:  2003-02-13       Impact factor: 22.113

5.  Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.

Authors:  Liat Rainis; Dan Bercovich; Sabine Strehl; Andrea Teigler-Schlegel; Batia Stark; Jan Trka; Ninette Amariglio; Andrea Biondi; Inna Muler; Gideon Rechavi; Helena Kempski; Oskar A Haas; Shai Izraeli
Journal:  Blood       Date:  2003-03-20       Impact factor: 22.113

Review 6.  Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins.

Authors:  J E Darnell; I M Kerr; G R Stark
Journal:  Science       Date:  1994-06-03       Impact factor: 47.728

7.  Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development.

Authors:  T Matsuyama; T Kimura; M Kitagawa; K Pfeffer; T Kawakami; N Watanabe; T M Kündig; R Amakawa; K Kishihara; A Wakeham
Journal:  Cell       Date:  1993-10-08       Impact factor: 41.582

Review 8.  The role of interferon-alpha in the treatment of chronic myeloid leukemia.

Authors:  Lisa A Kujawski; Moshe Talpaz
Journal:  Cytokine Growth Factor Rev       Date:  2007-08-20       Impact factor: 7.638

Review 9.  Megakaryoblastic leukemia and Down's syndrome: a review.

Authors:  A Zipursky; M Peeters; A Poon
Journal:  Pediatr Hematol Oncol       Date:  1987       Impact factor: 1.969

10.  Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder.

Authors:  Jürgen Groet; Suzanne McElwaine; Monica Spinelli; Andrea Rinaldi; Ingo Burtscher; Claire Mulligan; Afua Mensah; Simona Cavani; Franca Dagna-Bricarelli; Giuseppe Basso; Finbarr E Cotter; Dean Nizetic
Journal:  Lancet       Date:  2003-05-10       Impact factor: 79.321

View more
  18 in total

1.  Genome-wide Association Study of Platelet Count Identifies Ancestry-Specific Loci in Hispanic/Latino Americans.

Authors:  Ursula M Schick; Deepti Jain; Chani J Hodonsky; Jean V Morrison; James P Davis; Lisa Brown; Tamar Sofer; Matthew P Conomos; Claudia Schurmann; Caitlin P McHugh; Sarah C Nelson; Swarooparani Vadlamudi; Adrienne Stilp; Anna Plantinga; Leslie Baier; Stephanie A Bien; Stephanie M Gogarten; Cecelia A Laurie; Kent D Taylor; Yongmei Liu; Paul L Auer; Nora Franceschini; Adam Szpiro; Ken Rice; Kathleen F Kerr; Jerome I Rotter; Robert L Hanson; George Papanicolaou; Stephen S Rich; Ruth J F Loos; Brian L Browning; Sharon R Browning; Bruce S Weir; Cathy C Laurie; Karen L Mohlke; Kari E North; Timothy A Thornton; Alex P Reiner
Journal:  Am J Hum Genet       Date:  2016-01-21       Impact factor: 11.025

2.  Neonatal expression of RNA-binding protein IGF2BP3 regulates the human fetal-adult megakaryocyte transition.

Authors:  Kamaleldin E Elagib; Chih-Huan Lu; Goar Mosoyan; Shadi Khalil; Ewelina Zasadzińska; Daniel R Foltz; Peter Balogh; Alejandro A Gru; Deborah A Fuchs; Lisa M Rimsza; Els Verhoeyen; Miriam Sansó; Robert P Fisher; Camelia Iancu-Rubin; Adam N Goldfarb
Journal:  J Clin Invest       Date:  2017-05-08       Impact factor: 14.808

3.  Myeloid Proliferations Associated with Down Syndrome.

Authors:  Alan B Cantor
Journal:  J Hematop       Date:  2014-12-14       Impact factor: 0.196

Review 4.  Cohesin Mutations in Myeloid Malignancies.

Authors:  Joseph B Fisher; Maureen McNulty; Michael J Burke; John D Crispino; Sridhar Rao
Journal:  Trends Cancer       Date:  2017-04

5.  Pluripotent stem cells reveal erythroid-specific activities of the GATA1 N-terminus.

Authors:  Marta Byrska-Bishop; Daniel VanDorn; Amy E Campbell; Marisol Betensky; Philip R Arca; Yu Yao; Paul Gadue; Fernando F Costa; Richard L Nemiroff; Gerd A Blobel; Deborah L French; Ross C Hardison; Mitchell J Weiss; Stella T Chou
Journal:  J Clin Invest       Date:  2015-01-26       Impact factor: 14.808

Review 6.  Megakaryocyte ontogeny: Clinical and molecular significance.

Authors:  Kamaleldin E Elagib; Ashton T Brock; Adam N Goldfarb
Journal:  Exp Hematol       Date:  2018-03-02       Impact factor: 3.084

7.  Developmental Stage-Specific Manifestations of Absent TPO/c-MPL Signalling in Newborn Mice.

Authors:  Viola Lorenz; Haley Ramsey; Zhi-Jian Liu; Joseph Italiano; Karin Hoffmeister; Sihem Bihorel; Donald Mager; Zhongbo Hu; William B Slayton; Benjamin T Kile; Martha Sola-Visner; Francisca Ferrer-Marin
Journal:  Thromb Haemost       Date:  2017-12-06       Impact factor: 5.249

Review 8.  The prenatal origins of cancer.

Authors:  Glenn M Marshall; Daniel R Carter; Belamy B Cheung; Tao Liu; Marion K Mateos; Justin G Meyerowitz; William A Weiss
Journal:  Nat Rev Cancer       Date:  2014-03-06       Impact factor: 60.716

Review 9.  Changes in megakaryopoiesis over ontogeny and their implications in health and disease.

Authors:  Patricia Davenport; Zhi-Jian Liu; Martha Sola-Visner
Journal:  Platelets       Date:  2020-03-21       Impact factor: 3.862

Review 10.  Down syndrome and leukemia: insights into leukemogenesis and translational targets.

Authors:  Marion K Mateos; Draga Barbaric; Sally-Anne Byatt; Rosemary Sutton; Glenn M Marshall
Journal:  Transl Pediatr       Date:  2015-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.